Suppression of the Raf/MEK/ERK Signaling Cascade and Inhibition of Angiogenesis by the Carboxyl Terminus of Angiopoietin-Like Protein 4
- 1 May 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (5), 835-840
- https://doi.org/10.1161/atvbaha.107.157776
Abstract
Objectives— Angiopoietin-like protein 4 (Angptl4) is a secreted glycoprotein that has recently been implicated in the regulation of angiogenesis and metastasis. This study aimed to investigate the structural and cellular basis underlying the biological actions of Angptl4. Methods and Results— Circulating Angptl4 was proteolytically cleaved into NH2-terminal coiled-coil domain (N-Angptl4) and COOH-terminal fibrinogen-like domain (C-Angptl4). Using amino acid sequencing analysis, we identified a major cleavage site between Lys 168 and Leu 169 and a minor cleavage site between Lys 170 and Met 171 in mouse Angptl4. C-Angptl4, but not N-Angptl4, potently inhibited both bFGF- and VEGF-induced cell proliferation, migration, and tubule formation in endothelial cells, and prevented neovascularization in mice. Treatment of C-Angptl4 with PNGase F (an N -glycosidase) ablated its N-linked glycosylation, and also significantly attenuated its antiangiogenic activities. C-Angptl4 blocked bFGF-induced activation of ERK1/2 MAP kinase, but had no obvious effect on Akt and P38 MAP kinase. Furthermore, C-Angptl4 abrogated bFGF-induced phosphorylation of Raf-1 and MEK1/2, whereas neither auto-phosphorylation of FGF receptor-1 nor activation of Ras was affected, suggesting that the blockage occurs at the level of Raf-1 activation. Conclusions— The carboxyl terminus of Angptl4 alone is sufficient to suppress angiogenesis, possibly through inhibiting the Raf/MEK/ERK1/2 MAP kinase pathway in endothelial cells.Keywords
This publication has 29 references indexed in Scilit:
- Angiogenesis: an organizing principle for drug discovery?Nature Reviews Drug Discovery, 2007
- Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissueProceedings of the National Academy of Sciences of the United States of America, 2006
- Angiogenesis—a new target for future therapyVascular Pharmacology, 2006
- Angiopoietins and Angiopoietin-Like Proteins in AngiogenesisEndothelium, 2006
- Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in miceProceedings of the National Academy of Sciences of the United States of America, 2005
- Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4Journal of Lipid Research, 2004
- The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate TreatmentPublished by Elsevier BV ,2004
- Angiopoietin-Related/Angiopoietin-Like Proteins Regulate AngiogenesisInternational Journal of Hematology, 2004
- Peroxisome Proliferator-Activated Receptor γ Target Gene Encoding a Novel Angiopoietin-Related Protein Associated with Adipose DifferentiationMolecular and Cellular Biology, 2000
- Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosisBiochemical Journal, 2000